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Background: Liver – related mortality and morbidity are an increasing burden worldwide.  
Aim: To outline the pattern of liver abnormalities at a tertiary hospital in KwaZulu Natal (KZN), 
Durban, South Africa, during the era of the HIV epidemic. 
Methods: This cross-sectional, retrospective study conducted medical records review of all patients 
found to have liver abnormalities based on clinical, laboratory, and radiological profile, admitted to 
the medical wards for the period between June 2016 to December 2016. 
Results: A total of 157 patients were included, of which 63.1% were males, and 91.7% were black, 
with a median age of 41 years (IQR, 32–54). Sixty – six (42.0%) patients were HIV negative; 91 
(57.9%) were HIV infected, of which 51 (56.0%) were on antiretroviral therapy. Only 15 (29.4%) had 
an HIV viral load of < 50 copies/mL and 21 (30.9%) with a CD4+ count of ≥ 200 cells/mm3. In HIV 
negative, heart failure (48.5%) was the main cause of liver abnormalities (p-value < 0.001), whereas 
in HIV infected, abdominal TB (24.2%) and DILI (18.7%) were the commonest. Sixty- seven (42.7%) 
patients died while admitted, and leading causes were HIV/AIDS (40.3%), hypertension (13.4%), and 
metastatic cancer (13.4%). 
Conclusion: In HIV infected patients, abdominal TB was common, which was consistent with the 
common presenting symptoms of fever and vomiting in this group; whereas in HIV negative, heart 
failure was the commonest which was also consistent with the leading presenting symptoms of 
abdominal distension and ascites, and comorbid conditions of hypertension, diabetes mellitus, and 
dyslipidaemia which are all risk factors of cardiac diseases. Also, mortality was significantly high, 
and the leading causes were HIV/AIDS, hypertension, and advanced malignancy, which underscores 
the need to strengthen community-based screening programs for both communicable and non-









Chapter 1: Background and literature review 
1. Introduction 
Although significant work on various aspects of liver pathology has been done worldwide, including 
South Africa, a new spectrum of diseases is emerging mainly because of health evolution. We are 
now seeing an increasing prevalence of liver-related lifestyle disorders, namely non-alcoholic fatty 
liver disease (NAFLD) with resultant liver cirrhosis and thus the rising frequency of hepatocellular 
carcinoma (HCC) (1, 2). 
Furthermore, the HIV/AIDS epidemic and access to antiretroviral therapy continue to change the 
disease profile. Amongst other conditions, liver pathology continues to burden HIV infected 
population with a mortality rate of about 15% according to the Data Collection on Adverse Events of 
Anti- HIV Drugs study (3). 
1.1. Liver abnormalities 
1.1.1. Anatomical overview and physiology of the liver and biliary system 
The liver is the biggest vital organ in the body, representing 1.5 – 2.5% of body weight, which 
amounts to 1400 – 1800g in adults (4, 5). It has numerous functions, including bile production, fat-
soluble vitamin storage, and metabolism of drugs and bilirubin (6). The liver receives nearly 25% of 
the cardiac output via two sources; oxygen-rich blood supply through the hepatic artery and nutrient-
rich blood from the stomach, intestines, pancreas, and spleen through the portal vein (7).  
 
Macroscopically, the liver is divided into right and left lobes and further subdivided into eight 
independent segments. Each segment has its portal pedicle, consisting of the hepatic arterial branch, 
portal branch, and the bile duct with a separate hepatic venous branch (4). 
 
Microscopically, the liver is organized into structural units called lobules. However, functionally it is 
organized into acini, the smallest functional units containing a small portal tract at the center and 
terminal hepatic venules at the periphery. The acinus is divided into three zones; zone 1 surrounds the 
portal tract, zone 3 surrounds the hepatic venule, and the intervening hepatocytes constitute zone 2. 
Blood from the portal tract flows through these zones to the venule with a decreasing oxygen and 
nutrient gradient (8, 9). The biliary tract collects, stores, concentrates and delivers bile secreted by the 






1.2.2.  Mechanism and causes of liver abnormalities  
As an organ with a complex structure, high vascular supply, and increased metabolic activity, the liver 
is particularly susceptible to damage (9, 12). Liver abnormalities generally occur via five 
mechanisms, namely, inflammation (viral hepatitis, drug-induced liver injury (DILI), alcoholic 
hepatitis, autoimmune hepatitis), excessive storage (non-alcoholic fatty liver, Wilson's disease, 
hemochromatosis), infiltration (hepatocellular carcinoma, metastatic tumour, tuberculosis), vascular 
congestion (congestive cardiac failure, cor-pulmonale, Budd-Chiari syndrome) and biliary obstruction 
(choledocholithiasis, cholangiocarcinoma, choledochal cyst) (13, 14). Ischemic hepatitis is another 
well-recognized entity resulting from reduced oxygen delivery to the liver, and the term hepatitis is 
somewhat of a misnomer since an inflammatory process does not mediate the injury but hepatocytes 
necrosis (15). 
1.1.3. Clinical features 
In the acute phase, patients may present with non-specific symptoms such as malaise, anorexia, fever, 
and jaundice appear as the illness progresses; and clinical examination may be normal or reveal 
jaundice, hepatomegaly, and hepatic pain. If the insult to the liver is not removed, fibrosis may occur 
and eventually cirrhosis. Clinical signs such as spider neavi, palmar erythema may be seen, but these 
are not specific as they may be seen in normal people and pregnant women, and may occur in both 
acute and chronic liver disease. In males with chronic liver disease, particularly related to alcohol use, 
signs of hyperestrogenemia, namely gynecomastia, testicular atrophy, loss of male pattern hair 
distribution, may be seen. With advanced liver disease, ascites, oedema, dilated abdominal veins, feto-
hepaticus, asterixis, confusion, and coma may be found (16) 
1.1.4. Diagnosis and grading of liver abnormalities 
Liver function test 
There are several blood tests available that are useful in assessing the status of the liver. The most 
commonly used tests in clinical practice include the serum aminotransferases, bilirubin, alkaline 
phosphatase, albumin, and prothrombin time; collectively termed “liver function tests”. These tests 
are useful in guiding management by determining the pattern of liver disease, classified as either 
hepatocellular, cholestatic (obstructive), or mixed; and the degree of severity (1) 
Imaging 
Ultrasound is a non-invasive and inexpensive screening tool in patients presenting with abnormal liver 
function tests. It may hint on liver morphology, biliary system abnormalities, infiltrative processes, 




Magnetic resonance cholangiopancreatography (MRCP), both of which are minimally invasive. They 
provide precise depictions of the biliary system, characterize the liver lesion, and delineate vascular 
anatomy (20). However, in a patient with a cholestatic pattern on liver function test, with or without 
dilated MRCP is preferable to CT since it can also provide additional information regarding biliary 
flow (21, 22) 
The Fibroscan (ultrasound elastography) is a simple, non-invasive test to rule in/out advanced fibrosis 
and cirrhosis.  It works by measuring the sound wave's velocity passing through the liver and then 
converts those into a liver stiffness measurement. Since Fibroscan test results are promptly obtained, 
clinicians can use them to make decisions during the patient's visit; but technical limitations of the test 
preclude its use in patients with ascites and morbid obesity (23). 
Liver Biopsy 
Liver biopsy is viewed as the gold standard in diagnosing liver pathology since it provides otherwise 
unobtainable qualitative information regarding the liver's structural integrity and the type and degree 
of injury (24). However, several factors are limiting its use; (i) It is contraindicated in the presence of 
severe coagulopathy, infection of the hepatic bed, extrahepatic biliary obstruction, possible vascular 
lesions, and hydatid disease. (ii) There may be a misdiagnosis and incorrect staging if the biopsied 
samples are not representative of the liver's rest. (iii) The limited number of experienced clinicians to 
perform this invasive procedure and experienced histopathologists to analyze the sample once 
obtained, particularly in the developing countries. (v) Histology results may be non-specific and non-
diagnostic, for example, in drug and toxin-induced injury, overwhelming sepsis (24, 25) 
Miscellaneous investigations 
Other useful specific tests include toxicology screen and drug tests such as paracetamol level, viral 
hepatitis serology, autoimmune markers, ceruloplasmin, urine copper, iron saturation, serum ferritin, 
and alpha-fetoprotein (26, 27).  
Those patients with abnormal liver function and morphology presenting with ascites, peritoneal fluid 
analysis helps determine whether the ascites is due to portal hypertension-related causes or secondary 
causes. Apart from the fluid's macroscopic analysis, the initial step is to determine the serum-ascites 
albumin gradient (SAAG). A gradient of more than 1.1g/dl indicates portal hypertension, and that of 
less than 1.1g/dl indicates nonportal hypertension and suggests the peritoneal cause.  
If abdominal tuberculosis (TB) is suspected, peritoneal fluid Adenosine deaminase (ADA) may help. 
ADA of more than 30 U/L has a sensitivity of 100% (28). Microbiology investigations, namely smear 
for acid-fast bacilli (AFB), modified polymerase chain reaction (PCR) technique for mycobacterium 




However, AFB smear has a low yield with a reported sensitivity of 0%–6%. GeneXpert is always 
useful for the early detection of mycobacterium tuberculosis. A systemic review by Maynard-Smith et 
al. revealed gene Xpert median sensitivities of 0.85 (IQR, 075 -1.00) when testing non-pleural serous 
fluids, including ascites. Although present data support the current implementation of this assay for 
EPTB diagnosis, further studies are needed to expand the evidence base to use this assay. (29). 
Mycobacterial culture has a sensitivity of up to 50%; however, results may take 3-6 weeks to obtain, 
delaying therapy (30-32). 
1.1.5.  Epidemiology 
It is estimated that 844 million people have liver disease, with a global mortality rate of 2 million 
deaths per year (33). Liver disease has been ranked the 2nd commonest cause of mortality amongst all 
digestive diseases in the United States of America, and number five in Europe (34, 35). In China, 
approximately 300 million people have liver disease, and leading causes are non-alcoholic fatty liver 
disease (NAFLD) (49.3%), viral hepatitis B (HBV) (22.9%), alcoholic liver disease (ALD) (14.8%), 
and viral hepatitis C (3.2%) (36). It is noted that cirrhosis-related mortality doubled between 1980 and 
2010 in Sub-Saharan Africa, and most cases of cirrhosis were due to hepatitis B virus (HBV), alcohol 
misuse, and hepatitis C virus (HCV) (37). However, recent data on the overall burden of liver 
abnormalities in Africa is limited. A descriptive study by Kruger et al. conducted in Western Cape 
province in South Africa revealed that Non-alcoholic fatty liver disease (NAFLD) is common in this 
population, confirmed in 111(87%) patients (2). A recent cohort study of 301 biopsied patients with 
HIV/AIDS conducted in Cape Town, South Africa, showed that drug-induced liver injury (42%), 
granulomatous inflammation (29%), non-alcoholic steatosis or steatohepatitis (19%), and hepatitis B 
(19%) were the most common findings (38). 
 1.2. HIV/AIDS and Liver  
In 2017, approximately 36.9 million people were living with human immunodeficiency virus (HIV) 
worldwide, of which 7.7 million were South Africans; and access to antiretroviral therapy (ARTs) has 
decreased mortality due to acquired immunodeficiency syndrome (AIDS) (39-41). 
Susceptibility to tuberculosis, hepatitis B virus (HBV), and hepatitis C virus (HCV) co-infection, 
medication-related hepatotoxicity, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) are 
an increasing global burden in HIV infected patients (3, 42).  
Globally, an estimated 2-4 million people living with HIV have the hepatitis B virus (HBV) co-
infection, and 4-5 million have hepatitis C virus (HCV) co-infection (43). In Sub-Saharan Africa, the 
mean prevalence of HBV is 15%, and HCV is 7% (44, 45). Dual infection with HIV and HBV or 




hepatotoxicity and liver disease; this may also impact the selection of specific drugs dually active 
against HBV and HIV (43). 
Tuberculosis (TB) is the most common opportunistic infection leading to morbidity and mortality in 
HIV infected people (46). Abdominal TB with liver involvement is one of the common 
extrapulmonary manifestations in advanced HIV infected patients with mortality due to diagnostic 
and treatment challenges (47-49) 
Drug-induced liver injury (DILI) is common, complicating the introduction of TB treatment in 5- 33% 
and that of ARTs in 9 - 30% (50). Commonly used antiretroviral drugs (Efavirenz, Nevirapine, and 
Lopinavir/Ritonavir), anti-TB drugs (Rifampicin, Rifabutin, Isoniazid, Pyrazinamide, Bedaquiline and 
many second-line drugs, including quinolones) and Sulfamethoxazole & Trimethoprim may cause 
hepatitis, steatohepatitis, and transaminitis (51). The mechanism of liver injury due to these drugs is 
mostly due to idiosyncratic drug reaction. The occurrence of hepatitis is usually unpredictable, may 
occur at any time during or shortly after exposure to the drug, and the response is not as dose-
dependent as the injury associated with direct hepatotoxicity (16) 
Non-Alcoholic Fatty Liver Disease (NAFLD) is significant, with a prevalence of up to 50%.  
NAFLD's pathogenesis and the reasons for progression to non-alcoholic steatohepatitis (NASH) are 
still not fully elucidated, but insulin resistance, mitochondrial dysfunction, and dyslipidaemia seem to 
be the main drivers. Both HIV-infection itself and combination antiretroviral therapy can contribute to 
the development of NAFLD/NASH (52). 
Although the role of alcohol abuse on liver disease in HIV infected population has not been well 
defined, evidence suggests that alcohol abuse is prevalent among this population and can 
independently contribute to liver disease progression. As a modifiable risk factor for liver disease, 
clinicians must provide counselling regarding alcohol consumption in this group (42, 53) 
1.3. Problem statement 
Although significant work on various aspects of liver pathology has been done worldwide, including 
in South Africa, a new spectrum of diseases is emerging because of health evolution. We are seeing an 
increasing prevalence of liver-related lifestyle disorders, namely non-alcoholic fatty liver disease 
(NAFLD) with resultant liver cirrhosis and thus the rising frequency of hepatocellular carcinoma 
(HCC) (1, 2). Furthermore, the HIV/AIDS epidemic and access to antiretroviral therapy continue to 
change the disease profile. Amongst other conditions, liver pathology continues to burden HIV 
infected population (38, 54-56). We hypothesize that, liver abnormalities are common in patients 




This study proposes to outline the pattern of liver abnormalities in Durban, South Africa, during the 
HIV epidemic era, to help clinicians working in resource constrained environments to formulate a 
rational management approach for prevention and early detection of clinical conditions associated with 
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Chapter 2: A submitted ready manuscript 
Assessment of the liver in an HIV era: Clinical, laboratory and radiological abnormalities 
Abstract 
Background: Liver – related mortality and morbidity are an increasing burden worldwide.  
Aim: To outline the pattern of liver abnormalities at a tertiary hospital in KwaZulu Natal (KZN), 
Durban, South Africa, in the HIV era.  
Methods: This cross-sectional, retrospective study conducted medical records review of all patients 
found to have liver abnormalities based on clinical, laboratory, and radiological profile, admitted to 
the medical wards for the period between June 2016 to December 2016. 
Results: A total of 157 patients were included, of which 63.1% were males, and 91.7% were black, 
with a median age of 41 years (IQR 32–54). Sixty – six (42.0%) patients were HIV negative; 91 
(57.9%) were HIV infected, of which 51 (56.0%) were on antiretroviral therapy. Only 15 (29.4%) had 
an HIV viral load of < 50 copies/mL and 21 (30.9%) with a CD4+ count of ≥ 200 cells/mm3, with 
median of 426 cells/mm3 (IQR, 268 – 780). In HIV negative, heart failure (48.5%) was the main 
cause of liver abnormalities (p-value < 0.001), whereas in HIV infected, abdominal TB (24.2%) and 
DILI (18.7%) were the commonest. Sixty-seven (42.7%) patients died while admitted, and leading 
causes were HIV/AIDS (40.3%), hypertension (13.4%), and metastatic cancer (13.4%). 
Conclusion: Heart failure, abdominal TB, and DILI were the leading causes of liver abnormalities in 
this cohort. Also, mortality was significantly high and main causes were HIV/AIDS, hypertension, 
and advanced cancer, which underscores the need to reinforce community-based screening programs 










Significant strides have been made over the years on various aspects of liver pathology worldwide. 
However, most of this progress is undermined by the emerging increase in the prevalence of lifestyle-
related liver disorders and the HIV/AIDS epidemic and related disorders. 
The liver pathology burdens the HIV infected population with a mortality rate of about 15% per year 
based on data from first world counties (3) Tuberculosis (TB) is the most common opportunistic 
infection in HIV infected patients, and disseminated TB with liver involvement is one of the most 
typical extrapulmonary manifestations in those with advanced disease, associated with high mortality 
owing to diagnostic and treatment challenges (46) (47-49).  
Dual infections affecting the liver complicate therapy; an estimated 2-4 million people living with HIV 
have hepatitis B virus (HBV) co-infection and 4-5 million have hepatitis C virus (HCV) co-infection 
(43); such dual infections complicate therapy with looping adverse effects of drug-related 
hepatotoxicity and progression to liver disease (43). 
Drug-induced liver injury (DILI) complicates the introduction of TB treatment in 5- 33% of patients 
and that of antiretroviral therapy in 9 - 30% (50). Commonly used ARTs, anti-TB drugs, and 
Sulfamethoxazole & Trimethoprim (co-trimoxazole) may cause hepatitis, steatohepatitis, and 
transaminitis (51). Liver injury from these drugs is mostly due to idiosyncratic drug reaction; the 
occurrence of hepatitis is usually unpredictable and may occur at any time after exposure. The response 
is not as dose-dependent as the injury associated with direct hepatotoxicity (16). 
There is an increasing prevalence of lifestyle-related liver disorders such as non-alcoholic fatty liver 
disease (NAFLD) with resultant liver cirrhosis and thus the rising frequency of hepatocellular 
carcinoma (HCC) (1, 2). In HIV-infected, NAFLD has a significant prevalence of up to 50%. Both 
HIV-infection and combined antiretroviral therapy contribute to the development of NAFLD (52).  
This study aims to outline the pattern of liver abnormalities in KwaZulu Natal (KZN), South Africa, in 
the era of the HIV epidemic. 
Methodology 
This study conducted a medical records' appraisal of admissions with evidence of liver abnormalities 
from June 2016 to December 2016 at a tertiary public hospital in Durban, South Africa. Records of 
patients aged 13 years and older found to have liver abnormalities based on clinical, laboratory, or 
radiological findings were selected.  
Data collection (Appendix D) included the following information: 




Clinical profile: the presence of symptoms of fever, vomiting, jaundice, abdominal pain, abdominal 
distension, signs of jaundice, oedema, lymphadenopathy, liver consistency, ascites, admission blood 
pressure, pulse, and temperature. Relevant medical history including HIV/AIDS status, medication 
such as Trimethoprim-Sulfamethoxazole, antiretroviral therapy, anti-tuberculous treatment, and 
alcohol use 
Laboratory parameters: Admission full blood count (FBC), urea and electrolytes, Liver function test 
(LFT), and the international normalized ratio (INR). Hepatitis A, B, and C serology, most recent CD4 
cell count and HIV viral load (within 6-12 months) where applicable. Microbiology and 
histopathology results 
Imaging: Ultrasound of the liver and its findings 
Study implementation and recruitment 
Names and hospital numbers of all patients were obtained from the hospital admissions register. Each 
patient's file was retrieved and reviewed by the principal investigator for eligibility. Files found to 
have records of liver abnormalities were selected and audited. Histological and other laboratory 
results, if missing, were obtained from the National Health Laboratory System (NHLS) database. 
Names and hospital numbers were removed when capturing the data to the collection sheet, and the 
new numbering system was used to avoid duplication. All data was handled by the research team 
only.  
Statistical analysis 
SPSS® 23.0 software (IBM Corp, Armonk, NY, USA) was used for data analysis. Data were assessed 
for normality, and non-parametric tests were used where relevant. Medians and interquartile ranges 
(IQR) were used for data not normally distributed. Pearson's chi-square test or Fisher's exact test were 
used in assessing the association between categorical variables. The significance for all tests was set 
at p <0.05. 
Ethics approval  
The ethics approval was obtained from the University of Kwa-Zulu Natal (UKZN) Biomedical 
Research Ethics committee (BREC reference no. BE401/16). Permission to conduct the study was 
obtained from the health system gatekeepers. 
Results 
There were 1849 admitted patients to the medical wards at King Edward VIII Hospital as per the 
admission register during the period under review. However, only 1277 patient's files were retrievable 






Figure 1: A flowchart of our study 
Of 157 patients, 99(63.1%) were males, and 144(91.7%) were black with a median age of 41 years 
(IQR, 32 – 54) Ninety -one (58.0%) were HIV infected, and sixty-six (42.0%) were negative. The 
difference observed in systolic blood pressure (SBP) between the two groups was statistically 
significant using Independent-Samples Mann-Whitney U Test (p-value = 0.024). Fever (36.3%), 
vomiting (44%), pallor ((58.2%) were common clinical findings in HIV infected, whereas, in HIV 
negative, abdominal distention (56.1%), ascites (51.5%) were common. Comorbidities of 
hypertension, diabetes, and dyslipidemia were common in HIV negative, found in 45.5%, 24.2%, and 
28.2%, respectively compared to HIV infected (p - values < 0.001) (Table 1). 
Table 1: Demographic and clinical characteristics (n =157) 
Characteristics All patients 
(n = 157) 
HIV negative 
(n = 66) 
HIV infected 
(n = 91) 
p - value 
(HIV negative vs 
HIV infected) 
 Median (IQR) Median (IQR) Median (IQR)  
Age (years): 41 (32 - 54)  53 (38 – 65) 37 (29 – 46) 0.030 
     
 Frequency (%) Frequency (%) Frequency (%)  
Sex:    
0.019 
Male 99 (63.1) 49 (74.2) 50 (54.9) 
Female 58 (36.9) 17 (25.8) 41 (45.1) 
Race:     
0.009 

























<120 98 (62.4) 35 (53.0) 63 (69.2) 
120 - 139 43 (27.4) 20 (30.3) 23 (25.3) 
≥ 140 16 (10.2) 11 (16.7) 5 (5.5) 
BP diastolic (mmHg):    
0.770 
 
< 80 126 (80.3) 54 (81.8) 72 (84.6) 
80 - 89 16 (10.2) 7 (10.6) 9 (9.9) 
≥ 90 15 (9.6) 5 (7.6) 10 (11) 















































 Pale stool 
 





 Dark urine 33 (21.0) 14 (21.2) 19 (20.9) 1.000 


























 Pallor 79 (50.3) 26 (39.4) 53 (58.2) 0.024 
Comorbidities:      











































42 (27.6) 16 (24.6) 
 
26 (29.9) 0.583 
Data expressed as frequency (%) or median (Interquartile ratio). TB = tuberculosis, BP = blood pressure, HBV = 
hepatitis B virus, HCV = hepatitis C virus. Known with positive hepatitis B surface antigen/anti – HCV before 
admission*. Statistically significant using Independent-Samples Mann-Whitney U Test**. 
TDF = tenofovir, 3TC = emtricitabine, EFV = efavirenz, NVP = nevirapine, AZT = zidovudine, LPV/rit = 
Lopinavir/ritonavir, ABC = abacavir. 
 
 
HIV infected had mean hemoglobin (Hb) of 9.34 (SD ± 2.66) g/dl (p-value = 0.001), white cell count 
(WCC) median of 7.10 x 109/L (IQR, 4.60 – 11.25) (p-value = 0.014), globulin fraction of 44 g/L 
(IQR, 39 – 55) (p-value = 0.027, and serum albumin median of 20 g/L (IQR, 16 – 27) (p-value = 
0.001 compared to HIV negative; all statically significant using Independent samples Mann-Whitney 







Table 2: Laboratory characteristics on admission (n = 157) 
Parameters HIV negative 
(n = 66) 
HIV infected 
(n = 91) 
P value (HIV 
negative vs HIV 
infected) 
 Mean ± SD Mean ± SD  
Hb (g/dl) 11.06 ± 3.05 9.34 ± 2.66 0.001** 
    
 Median (IQR) Median (IQR)  
WCC (109/L) 9.47 (5.98 – 13.87) 7.10 (4.60 – 11.25) 0.014** 
Platelets (109/L) 240 (137 – 366) 227 (127 – 340) 0.579 
Total protein (g/L)  68 (62 – 78) 68 (59 – 77) 0.758 
Globulin fraction (g/L) 42 (35 -49) 44 (39 – 55) 0.027** 
Albumin (g/L) 26 (20 – 33)  20 (16 – 27) 0.001** 
Total bilirubin (μmol/L) 35 (22 – 78)  45 (11 – 164) 0.773 
ALT (U/L) 46 (23 – 219) 84 (33 – 222) 0.065 
AST (U/L) 69 (33 – 300)  369 (83 – 460)  0.164 
ALP (U/L) 203 (145 – 337) 214 (145 – 354) 0.676 
GGT (U/L) 236 (100 – 344) 205 (96 – 300)) 0.208 
INR 1.30 (1.12 – 1.62)  1.32 (1.12 – 1.77)  0.518 
Data expressed as mean ± standard deviation or median (Interquartile ratio). Statistically, significant using 
Independent samples Mann-Whitney U Test. Significant level is 0.05** Hb = hemoglobin, WCC = white cell 
count, ALT = alanine aminotransferase, AST = aspartate transaminase, ALP = alkaline phosphatase, GGT = 
gamma-glutamyl transpeptidase, INR = international normalized ratio. 
 
Of 91 patients who were HIV infected, 51(56.0%) were on ART most of which were on “first – line 
“regimen comprising of TDF+3TC+EFV (90.2%). Twenty - one (30.9%) had a CD4+ count of > 200 
cells/mm3, with median of 426 cells/mm3 (IQR, 268 – 780), and 15 (29.4%) had an HIV viral load of 
< 50 copies/mL. Whereas 36 (70.6%) had detectable viral load with a median of 214000 copies/ mL 
(IQR, 11050 – 122000) (Table 3). 
Table 3: CD4+ cell count, HIV viral load and ART use in HIV infected (n = 91) 
Parameters Frequency (%) Median (IQR) 
CD4+ count (cells/mm3):   
< 200 47 (69.1) 73 (39 – 103) 




HIV viral load (copies/ mL): 
 
  
< 50 15 (29.4) 0 (0 – 0) 
≥ 50 36 (70.6) 214000 (11050 – 122000) 
Antiretroviral drug use: 51 (56.0) N/A 
ART combination:   
TDF+3TC+EFV 46 (90.2) N/A 
TDF+3TC+NVP 1 (2.0) N/A 
AZT+3TC+LPV/r 1 (2.0) N/A 
ABC+3TC+LPV/r 3 (5.8) N/A 
Data expressed as frequency (%) or median (Interquartile ratio).  
ART = Antiretroviral therapy, TDF = tenofovir, 3TC = emtricitabine, EFV = efavirenz, NVP = nevirapine, 
AZT = zidovudine, LPV/rit = Lopinavir/ritonavir, ABC = abacavir. 
 
Overall, heart failure (30.6%), abdominal TB (14.6%), and drug-induced liver injury (14.0%) were 
common causes of liver abnormalities. Compared to HIV negative, abdominal TB (24.2%) and drug-
induced liver injury (18.7 %) were the commonest in HIV infected, while in HIV negative, heart failure 
(48.5%) was the leading cause (p-value < 0.001). Other conditions including liver ischemia, 
choledocholithiasis, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, lymphoma, 
cholangiocarcinoma, AIDS-associated cholangiopathy, and disseminated histoplasmosis accounted for 
7% of all causes.  In 21 (13.4%) patients, causes of liver abnormalities were not established (Table 4). 
Table 4: Causes of liver of liver abnormality (n = 157) 
Parameters All patients 
(n = 157) 
HIV negative 
(n = 66) 
HIV infected 
(n = 91) 
P value (HIV 
negative vs 
HIV infected) 
 Frequency (%)  Frequency (%) Frequency (%)  
Heart failure 48 (30.6) 32 (48.5) 16 (17.6) < 0.001 
Abdominal TB 23 (14.6) 1 (1.5) 22 (24.2) < 0.001 
 DILI 22 (14.0) 5 (7.6) 17 (18.7) 0.048 
Acute hepatitis B 16(10.2) 3 (4.5) 13 (14.3) 0.046 
Alcoholic liver disease 8 (5.1) 7 (10.6) 1 (1.1) 0.010 
Liver metastasis 4 (2.5) 3 (4.5) 1 (1.1) 0.310 
HCC 3 (1.9) 2 (3.0) 1 (1.1) 0.573 
Other  11 (7.0) 5 (7.6) 6 (6.6) 1.000 
Unknown 21 (13.4) 7 (10.6) 14 (15.4) 0.385 
Data expressed as frequency (%). For counts less than 5 Fisher’s exact tests were used to assess association between 
categorical variables and Pearson’s Chi square test where appropriate. TB = tuberculosis, DILI = drug induced liver 
injury, HCC = hepatocellular carcinoma, NAFLD = non-alcoholic fatty liver disease 
Other = (liver ischaemia, choledocholithiasis, NAFLD, autoimmune hepatitis, lymphoma, cholangiocarcinoma, AIDS 





The diagnosis of abdominal TB was made based on constellation of tests, and the most utilised test 
was ultrasound (20), followed by ADA (4) and GXP (3). Liver biopsy was utilised in 2 patients 
(Table 5).   
Table 5: Investigations used to diagnose abdominal tuberculosis (n = 23) 
Parameters Frequency 
Ultrasound  20 
ADA  4 
GXP 3 
Liver biopsy 2 
Data expressed as frequency. ADA = adenosine deaminase.  GXP = Gene Xpert 
In patients with drug-induced liver injury (DILI), associated drugs were Isoniazid, Rifampicin, 
Ethambutol, and Pyridoxine (IREP) combination therapy (54.6%), efavirenz (22.7%), INH (13.6%), 
and paracetamol overdose (9.1%). 
 











There were 67 (43%) deaths in this cohorts, of which HIV/AIDS (40.3%), hypertension (13.4%) and 
metastatic cancer (13.4%) were the common documented causes. Alcoholic liver disease, hepatitis B 




Parameters Frequency (%) 
HIV/AIDS 27 (40.3) 
Hypertension 9 (13.4) 
Metastatic cancer 9 (13.4) 
Alcoholic liver disease 5 (7.5) 
Severe sepsis 4 (6.0) 
Diabetes mellitus 3 (4.5) 
Hepatitis B 3 (4.5) 
DILI 2 (3.0) 
Other 5(7.5) 





Liver abnormalities are common in patients admitted to the medical wards. In this cohort of 12% of 
patients whose files were accessed and reviewed had liver abnormalities. 
The majority of patients were young and HIV infected. This finding is comparable to other studies 
conducted in other facilities in South Africa (21, 57). Most patients were males (p-value = 0.019), but 
the exact reason for male predominance is beyond this study's scope. The racial demographic 
differences likely reflect the general provincial demographics that access the public health system. 
In patient with HIV infection fever (p value = 0.001), vomiting (p value = 0.012) and pallor (p value = 
0.025) were common compared to those who were HIV negative; this is consistent with the clinical 
manifestation of TB which was high in HIV infected group (p value < 0.001) compared to HIV 
negative. HIV negative patients had abdominal distention (p value = 0.024) and ascites (p value = 
0.003); and hypertension (p value <0.001), diabetes mellitus (p value <0.001) and dyslipidaemia (p 
value <0.001) were common, all of which were consistent with the common diagnosis of heart failure 
which was high compared to HIV infected (p value <0.001).   
In this study, DILI was expected, although frequency was low compared to other studies conducted in 
South Africa (21, 57). Anti-tuberculous medication (IREF and INH prophylaxis) and EFV were the 
significant causes of DILI in this study; however, for the treatment of TB, it was not clear which 
specific anti-tuberculous drug was the cause since patients were on combination therapy.  
Liver biopsy is viewed as the gold standard in diagnosing liver pathology, but due to the invasive 
nature of this procedure and the need for experienced personnel to analyses the biopsied specimen, it 
is proven to be the challenge in clinical practice (30, 31). The majority of documented diagnoses were 
based on other supplementary tests; liver biopsy was performed in only two patients in this study's 
tuberculosis diagnosis. The reason for a liver biopsy to be rarely performed is not known, but thought 
to be due to several factors, (i) less invasive procedures may have been adequate to make the 
diagnosis (liver congestion due to heart failure) (ii) those who required biopsy may have been 
unstable for the procedure to be performed; this is supported by looking at the number of deaths in 
this study. 
The number of HIV infected patients on ART (56.0%), and those who had an undetectable HIV viral 
load (29.4%) were far below the aimed targets for 90-90-90 strategy for eliminating HIV/AIDS 
disease burden in this cohort. Even though data on ART duration was not collected, the frequency of 
patients with CD4+ <200 cells/mm3, low mean haemoglobin of 9.34 (SD ± 2.66) g/dl, and low median 
albumin of 20 g/L (IQR, 16 – 27) suggest that most patients infected with HIV had the advanced 





This cohort's limitations were that it was impossible to access histology that confirms liver 
abnormalities for the majority of patients, data on body mass index (BMI), serum lipids levels, the 
quantity of alcohol intake, duration, and doses of hepatotoxic drugs, including herbal medication. 
However, this study does report on the clinical characteristics of patients with liver abnormalities, 
both HIV-infected and HIV-negative. 
Conclusion: 
The majority of patients with HIV infection had a symptom of fever, vomiting, and were found to 
have to abdominal TB as the commonest cause of liver abnormality; while the majority of those that 
were HIV negative had abdominal distention and ascites, with risk factors of heart failure, such as 
hypertension, diabetes mellitus, and dyslipidaemia. These patients had heart failure as the commonest 
cause of liver abnormalities. Also, there was a high number of mortalities in this cohort, and the 
commonly reported causes were HIV/AIDS, hypertension, and advanced cancer. The findings in this 
cohort could assist health care officials to formulate strategies to strengthen community-based 
programs for screening of communicable diseases such as HIV/AIDS and TB including non-
communicable disease such as hypertension and diabetes mellitus at a community level, for early 
detection and referral to care in addition to emphasizing treatment adherence; and clinicians working 
in this resource-constrained environment may utilise this data to formulate a rational approach for 
early detection and management of common clinical conditions associated with liver abnormalities.  
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Appendix A: Research protocol 
Title of the study: Assessment of the liver in an HIV era: Clinical, laboratory and radiological 
abnormalities 
Aims of the study 
• To determine causes of liver abnormalities, including histological diagnosis in patients 
admitted to the medical wards at King Edward VIII hospital 
• To compare the prevalent causes of liver abnormalities in HIV infected and HIV negative 
Objectives of the study 
• To identify patients with liver abnormalities admitted to the medical wards 
• To ascertain demographic, clinical, laboratory and radiological characteristics of patients with 
liver abnormalities 
• To identify patients with HIV infection and HIV negative with liver abnormalities 
Background and literature review 
1.Introduction 
Globally, liver-related morbidity and mortality are an increasing burden. Although significant work on 
various aspects of liver pathology has been done worldwide, a new spectrum of diseases is emerging 
because of health evolution. We are seeing an increasing prevalence of liver-related lifestyle disorders, 
namely non-alcoholic fatty liver disease (NAFLD) with resultant liver cirrhosis and thus rising 
frequency of hepatocellular carcinoma (HCC) (1, 2). 
Furthermore, the HIV/AIDS epidemic and access to antiretroviral therapy continue to change the 
disease profile. Amongst other conditions, liver pathology continues to burden HIV infected population 
with a mortality rate of about 15% according to the Data Collection on Adverse Events of Anti- HIV 
Drugs study (3). 
1.1. Liver abnormalities 
1.1.1. Anatomical overview and physiology of the liver and biliary system 
The liver is the biggest vital organ in the body, representing 1.5 – 2.5% of body weight which amounts  
he liver is the biggest vital organ in the body, representing 1.5 – 2.5% of body weight, which amounts 
to 1400 – 1800g in adults (4, 5). It has numerous functions, including bile production, fat-soluble 




output via two sources; oxygen-rich blood supply through the hepatic artery and nutrient-rich blood 
from the stomach, intestines, pancreas, and spleen through the portal vein (7). Macroscopically, the 
liver is divided into right and left lobes and further subdivided into eight independent segments. Each 
segment has its portal pedicle, consisting of the hepatic arterial branch, portal branch, and the bile duct 
with a separate hepatic venous branch (4). 
Microscopically, the liver is organized into structural units called lobules. However, functionally it is 
organized into acini, the smallest functional units containing a small portal tract at the center and 
terminal hepatic venules at the periphery. The acinus is divided into three zones; zone 1 surrounds the 
portal tract, zone 3 surrounds the hepatic venule, and the intervening hepatocytes constitute zone 2. 
Blood from the portal tract flows through these zones to the venule with a decreasing oxygen and 
nutrient gradient (8, 9). The biliary tract collects, stores, concentrates, and delivers bile secreted by the 
liver, and the bile ducts anatomy follows that of the portal system and segmentation of the liver (10, 
11). 
 
1.1.2.  Mechanism and causes of liver abnormalities  
As an organ with a complex structure, high vascular supply, and increased metabolic activity, the liver 
is particularly susceptible to damage (9, 12). Liver abnormality generally occurs via five mechanisms, 
namely, inflammation (viral hepatitis, drug-induced liver injury, alcoholic hepatitis, autoimmune 
hepatitis), excessive storage (non-alcoholic fatty liver, Wilson's disease, hemochromatosis), 
infiltration (hepatocellular carcinoma, metastatic tumor, tuberculosis), vascular congestion 
(congestive cardiac failure, cor-pulmonale, Budd-Chiari syndrome) and biliary obstruction 
(choledocholithiasis, cholangiocarcinoma, choledochal cyst) (13, 14). ischemic hepatitis is another 
well-recognized entity resulting from reduced oxygen delivery to the liver, and the term hepatitis is 
somewhat of a misnomer since an inflammatory process does not mediate the injury but hepatocytes 
necrosis (15). 
1.1.3. Clinical features 
In the acute phase, patients may present with non-specific symptoms such as malaise, anorexia, fever, 
and jaundice appear as the illness progresses; and clinical examination may be normal or reveal 
jaundice, hepatomegaly, and hepatic pain. If the insult to the liver is not removed, fibrosis may occur 
and eventually cirrhosis. Clinical signs such as spider naevi, palmar erythema may be seen, but these 
are not specific as they may be seen in normal people and pregnant women, and may occur in both 
acute and chronic liver disease. In males with chronic liver disease, particularly related to alcohol use, 
signs of hyperestrogenemia, namely gynecomastia, testicular atrophy, loss of male pattern hair 
distribution, may be seen. With advanced liver disease, ascites, edema, dilated abdominal veins, feto-




1.1.4. Diagnosis and grading of liver abnormalities 
Liver function test 
There are several blood tests available that are useful in assessing the status of the liver. The most 
commonly used clinical practice tests include the serum aminotransferases, bilirubin, alkaline 
phosphatase, albumin, and prothrombin time, collectively termed "liver function tests." These tests are 
useful in guiding management by determining the pattern of liver disease, classified as either 
hepatocellular, cholestatic (obstructive), or mixed; and the degree of severity (17) 
Imaging 
Ultrasound is a non-invasive and inexpensive screening tool in patients presenting with abnormal liver 
function tests. It may hint on liver morphology, biliary system abnormalities, infiltrative processes, 
and vascular dopplers (18, 19). Other imaging techniques are Computed tomography CT scan and 
Magnetic resonance cholangiopancreatography (MRCP), both of which are minimally invasive. They 
provide precise depictions of the biliary system, characterize the liver lesion, and delineate vascular 
anatomy (20). However, in a patient with a cholestatic pattern on liver function test, with or without 
dilated MRCP is preferable to CT since it can also provide additional information regarding biliary 
flow (21, 22) 
The Fibroscan (ultrasound elastography) is a simple, non-invasive test to rule in/out advanced fibrosis 
and cirrhosis.  It works by measuring the sound wave's velocity passing through the liver and then 
converts those into a liver stiffness measurement. Since Fibroscan test results are promptly obtained, 
clinicians can use them to make decisions during the patient's visit; but technical limitations of the test 
preclude its use in patients with ascites and morbid obesity (23). 
Liver Biopsy 
Liver biopsy is viewed as the gold standard in diagnosing liver pathology since it provides otherwise 
unobtainable qualitative information regarding the liver's structural integrity and the type and degree 
of injury (24). However, several factors are limiting its use; (i) It is contraindicated in the presence of 
severe coagulopathy, infection of the hepatic bed, extrahepatic biliary obstruction, possible vascular 
lesions, and hydatid disease. (ii) There may be a misdiagnosis and incorrect staging if the biopsied 
samples do not represent the liver's structural integrity. (iii) The limited number of experienced 
clinicians to perform this invasive procedure and experienced histopathologists to analyze the sample 
once obtained, particularly in the developing countries. (v) Histology results may be non-specific and 





Other useful specific tests include toxicology screen and drug tests such as paracetamol level, viral 
hepatitis serology, autoimmune markers, ceruloplasmin, urine copper, iron saturation, serum ferritin, 
and alpha-fetoprotein (26, 27).  
Those patients with abnormal liver function and morphology presenting with ascites, peritoneal fluid 
analysis helps determine whether the ascites is due to portal hypertension-related causes secondary 
causes. Apart from the fluid's macroscopic analysis, the initial step is to determine the serum-ascites 
albumin gradient (SAAG). A gradient of more than 1.1g/dl indicates portal hypertension, and that of 
less than 1.1g/dl indicates nonportal hypertension and suggests the peritoneal cause.  
If abdominal tuberculosis (TB) is suspected, peritoneal fluid Adenosine deaminase (ADA) may help. 
ADA of more than 30 U/L has a sensitivity of 100% and a specificity of 92-97% (28). Microbiology 
investigations, namely smear for acid-fast bacilli (AFB), modified polymerase chain reaction (PCR) 
technique for mycobacterium tuberculosis DNA (GeneXpert MTB/RIF assay), and mycobacterial 
culture may be performed. However, AFB smear has a low yield with a reported sensitivity of 0%–6%. 
GeneXpert is always useful for the early detection of mycobacterium tuberculosis. A systemic review 
by Maynard-Smith et al. revealed GeneXpert median sensitivities of 0.85 (IQR, 075 -1.00) when testing 
non-pleural serous fluids, including ascites. Although present data support the current implementation 
of this assay for EPTB diagnosis, further studies are needed to expand the evidence base to use this 
assay. (29). Mycobacterial culture has a sensitivity of up to 50%. However, results may take 3-6 weeks 
to obtain, which may delay therapy (30-32). 
Epidemiology 
It is estimated that 844 million people have liver disease, with a global mortality rate of 2 million deaths 
per year (33). Liver disease has been ranked the 2nd commonest cause of mortality amongst all digestive 
diseases in the United States of America, and number five in Europe (34, 35). In China, approximately 
300 million people have liver disease, and leading causes are non-alcoholic fatty liver disease 
(NAFLD), viral hepatitis B (HBV) (22.9%), alcoholic liver disease (ALD), and viral hepatitis C at 
49.3%, 22.9%, 14.8%, and 3.2% respectively (36).  
In Africa, data demonstrating the overall burden of liver disease is limited; however, it has been noted 
that cirrhosis-related mortality has doubled between 1980 and 2010 in Sub Saharan Africa; and most 
cases of cirrhosis were due to hepatitis B virus (HBV), alcohol misuse, and hepatitis C virus (HCV) 
(37). A descriptive study by Kruger et al. conducted in Western Cape province in South Africa revealed 
that Non-alcoholic fatty liver disease (NAFLD) is common in this population, confirmed in 111(87%) 
patients (2). A recent cohort study of 301 biopsied patients with HIV/AIDS conducted in Cape Town, 
South Africa, showed that drug-induced liver injury (42%), granulomatous inflammation (29%), non-




1.2. HIV/AIDS and Liver  
In 2017, approximately 36.9 million people were living with human immunodeficiency virus (HIV) 
worldwide, of which 7.7 million were South Africans; and access to antiretroviral therapy (ARTs) has 
decreased mortality due to acquired immunodeficiency syndrome (AIDS) (39-41). 
Susceptibility to tuberculosis, hepatitis B virus (HBV), and hepatitis C virus (HCV) co-infection, 
medication-related hepatotoxicity, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) are an 
increasing global burden in HIV infected patients. Liver-related mortality amongst these patients is 
about 15%; however, this data is from high-income countries (3, 42).  
Globally, an estimated 2-4 million people living with HIV have the hepatitis B virus (HBV) co-
infection, and 4-5 million have hepatitis C virus (HCV) co-infection (43). In Sub-Saharan Africa, the 
mean prevalence of HBV is 15%, and HCV is 7% (44, 45). Dual infection with HIV and HBV or HBC 
may complicate antiretroviral therapy delivery by increasing the risk of drug-related hepatotoxicity and 
liver disease; this may also impact the selection of specific drugs dually active against HBV and HIV 
(43). 
Tuberculosis (TB) is the most common opportunistic infection leading to morbidity and mortality in 
HIV infected people (46). Abdominal TB with liver involvement is one of the common extrapulmonary 
manifestations in advanced HIV infected patients with mortality due to diagnostic and treatment 
challenges (47-49) 
Drug-induced liver injury (DILI) is a common, complicating introduction of TB treatment in 5- 33% 
and ARTs in 9 - 30% (50). Commonly used antiretroviral drugs (Efavirenz, Nevirapine, and 
Lopinavir/Ritonavir), anti-TB drugs (Rifampicin, Rifabutin, Isoniazid, Pyrazinamide, Bedaquiline and 
many second-line drugs, including quinolones) and Sulfamethoxazole & Trimethoprim may cause 
hepatitis, steatohepatitis, and transaminitis (51). The mechanism of liver injury due to these drugs is 
mostly due to idiosyncratic drug reaction. The occurrence of hepatitis is usually unpredictable, may 
occur at any time during or shortly after exposure to the drug, and the response is not as clearly dose-
dependent as the injury associated with direct hepatotoxicity (16) 
Non-Alcoholic Fatty Liver Disease (NAFLD) is significant, with a prevalence of up to 50%. NAFLD's 
pathogenesis and the reasons for progression to non-alcoholic steatohepatitis (NASH) are still not fully 
elucidated, but insulin resistance, mitochondrial dysfunction, and dyslipidaemia seem to be the main 
drivers. Both HIV-infection itself and combination antiretroviral therapy can contribute to 
NAFLD/NASH (52). 
Although the role of alcohol abuse on liver disease in HIV infected population has not been well 




contribute to liver disease progression. As a modifiable risk factor for liver disease, clinicians must 
provide counselling regarding alcohol consumption in this group (42, 53) 
The purpose of this study is to outline the pattern of liver abnormalities in patients admitted to the 
medical wards at a tertiary teaching hospital in Durban, KwaZulu Natal, in the HIV era. The purpose 
of this study is to outline the pattern of liver abnormalities in patients admitted to the  
Methodology 
Study design 
Cross- sectional, retrospective study. Medical records review of all patients admitted to the medical 
wards, found to have liver abnormalities from June 2016 to December 2016 will be performed  
Setting 
 King Edward VIII Hospital in Durban, South Africa, which is a tertiary level public hospital and a 
teaching hospital complex supported by the University of KwaZulu Natal. 
Study population 
Patients age 13 years and older, both men and women from different racial groups 
Study sample 
Convenient sample depending on the number of patients identified and have met the inclusion criteria 
Inclusion criteria 
Patients from age 13 years and above 




Data collection will include the following information: 
Demographic: Age, gender and race 
Clinical: the presence of symptoms such as, fever, vomiting, jaundice, abdominal pain, abdominal 
distension; signs of jaundice, pallor, edema, lymphadenopathy, liver consistency, ascites if present 




status, medication such as Trimethoprim- Sulfamethoxazole, antiretroviral therapy, anti- tuberculous 
treatment and alcohol use 
Laboratory parameters: Admission full blood count (FBC), urea and electrolytes, Liver function test 
(LFT) and the international normalized ratio (INR). Hepatitis A, B and C, most recent CD4 cell count 
and HIV viral load (within 6-12 months) where applicable. Serology, microbiology and 
histopathology results 
Ultrasound of the liver and its findings 
Implementation and recruitment 
Names and hospital numbers of all patients admitted to the medical wards during the period between 
June 2016 to December 2016 will be obtained from the hospital admission register. Each patient's file 
will be retrieved and reviewed by the principal investigator for eligibility to be included in the study 
based on selection criteria. Those found to have evidence of liver abnormalities based on clinical, 
laboratory, and or radiological investigations will be further reviewed for required information, 
namely, clinical presentation, comorbid conditions, medication, laboratory and ultrasound findings, 
and outcomes. If missing on the patient's file, histological and other laboratory results will be obtained 
from the National Health Laboratory System (NHLS) database. Once retrieved, all data will be 
captured on the data collection sheet (Appendix D). Patient's names and hospital numbers will be 
removed between initial retrieval and recording in the database, and all patients will be identified by 
the numbering system to avoid duplication of information. Anonymous information will be captured 
into the Microsoft Excel database. 
Ethical considerations 
The study's approval will be obtained from the University of Kwa-Zulu Natal (UKZN) Biomedical 
Research Ethics committee (BREC). 
Since there will be no interaction with the patients, patient consent will not be taken. Permission to 
conduct the study will be obtained from King Edward VIII Hospital, and patients' information will be 
kept confidentially. 
Statistical analysis 
SPSS® 23.0 software (IBM Corp, Armonk, NY, USA) will be employed for data analysis.  Data were 
assessed for normality, and non-parametric tests were used where relevant. Medians and interquartile 




Limitations and strengths of the study 
Since this is a small study, it may not show the true reflection of the general population; and missing 
data is expected since this is a retrospective study. This study will be able to report on clinical data for 
patients, in addition to the laboratory and radiological data.   
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Appendix D: Data collection sheet 
Case number:  
Age:  
 
Gender:   Female                 Male 
 
Race  Black          White     Asian       Coloured 
Date of admission  
 
Presenting symptoms 
 Fever       vomiting          hematemesis         diarrhoea           
 
 
 yellow eyes         abdominal pain        abdominal distension/mass        
 
 Dark urine          asymptomatic  
 
 
Presenting clinical signs 
Vital signs 
BP ………mmHg           HR   ………bpm           T   …………⁰C              HGT 
………mmol/L 
 
 Jaundice      Pallor       Clubbing       Oedema     
 
 Lymphadenopathy, site(s): …………………       Ascites     
   
















 Hypertension            Dyslipidaemia              Diabetes Mellitus  
     
 Heart failure               abdominal TB   Hepatitis B/C        
  Other, Specify ……………                      
 
RVD      Positive      Negative     unknown   
If Positive 
CD4+ count __________         
VL __________ copies  
 ARVs: 
Alcohol intake    yes               no   
 
Laboratory investigations 
Parameters  Results 
Hb  
WCC   
Plts  











Total Cholesterol  
Triglycerides  
HDL Cholesterol  
LDL Cholesterol  
VCT (Rapid HIV test)  
HIV ELISA (if VCT negative)  
IF positive: CD4 count  
Viral load  
Hepatitis B: HBsAg 
                     Anti-HBc 
                     IgM anti-HBc 
                     Anti-HBs 
                     Titre 
 
Hepatitis C: HCV RNA 
                     Anti-HBV         
 
ANA  




Anticardiolipin antibody  
Antithyroid antibody  








Liver size: ……….cm 
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